Tiny study reveals how liver cirrhosis alters drug breakdown

NCT ID NCT05741385

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at how people with and without liver cirrhosis process five common medicines: caffeine, warfarin, omeprazole, metoprolol, and midazolam. Only 4 participants took part, including healthy volunteers and those with mild or moderate cirrhosis. Researchers took frequent blood samples to measure drug levels, aiming to understand how liver damage affects drug metabolism. The results may guide future drug development for people with liver disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: caffeine, warfarin, omeprazole, metoprolol, and midazolam
What this could lead to: If successful, this study could help researchers design better dosing guidelines for new medicines in people with liver cirrhosis.
What could go wrong: This is a very small, early-stage profiling study with only 4 participants. Results may not apply to all patients, and the medicines tested are already approved, so no new treatment is being developed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Locations

CRS Clinical Research Services Mannheim GmbH

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.